BRENNEN

Industries / Health / Healthcare / Weight-loss clinics

Compounded and copied drugs

Compounding means a pharmacy mixes a medicine itself instead of dispensing a factory-made product; when the new weight-loss drugs ran short, clinics and online services sold such copies, and fakes and, where patents ended, lawful generics followed.

7

Milestones achieved, from 2023 to 2026.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 2023

    Tenfold errors from vials

    The approved semaglutide comes in pens that click to set each dose, but compounded copies were often sold as vials with separate syringes. J. E. Lambson and colleagues at a regional US poison control center described three patients made ill by dosing mistakes: two had taken ten times the intended dose, one had measured in milliliters and "units" instead of milligrams, and one had received a vial and syringes with no instruction from the pharmacy. A later study by T. J. Mattingly of the University of Utah and colleagues found that reports of dosing and administration errors with GLP-1 drugs in the FDA's adverse event database rose from late 2022, a pattern not seen with insulin.

    LessonMoving the drug from a pen to a vial removed the pen's guard against overdose.

    europepmc.orgeuropepmc.org

    Credit

    J. E. Lambson, S. C. Flegal and A. R. Johnson; T. J. Mattingly, E. E. Duru and R. M. Conti

  2. 2024

    Test buys from illegal sellers

    A team from the University of Pécs in Hungary and the University of California San Diego checked 1,080 search results and found 59 illegal online pharmacies selling semaglutide without a prescription. It ordered from six: three vials arrived and none of the three pens did. Every vial held 28.6% to 38.7% more semaglutide than its label stated, but its purity was only 7.7% to 14.4% against the 99% claimed, and all contained endotoxin, a toxin from bacteria.

    europepmc.org

    Credit

    A. R. Ashraf, T. K. Mackey, A. Fittler and colleagues

  3. 2024

    Australia bans compounded copies

    On 27 May 2024 Australia's health department, on advice from the Therapeutic Goods Administration (TGA), the national medicines regulator, announced that pharmacies could no longer compound GLP-1 drugs such as semaglutide and tirzepatide from 1 October 2024. The government estimated that 20,000 people were using compounded versions; the chief executive of the insurer NIB put the number at about 70,000.

    australianpharmacist.com.au

    Credit

    Australian Department of Health and Aged Care; TGA

  4. 2025

    Tracing the powder

    Compounders mix copies from bulk drug powder. Marta Wosińska of the Brookings Institution matched FDA registration, drug-code and import records to find who shipped bulk semaglutide to the US. Between March 2023 and September 2024, 16 companies made 159 shipments; close to 60% of the plants holding drug codes for the powder had not been registered with the FDA before the shortage, and three Chinese firms behind 20% of the imported volume had never been inspected.

    brookings.edu

    Credit

    Marta E. Wosińska, Brookings Institution, April 2025

  5. 2025

    A border green list

    The FDA announced a "green list" of foreign makers of GLP-1 drug ingredients on 5 September 2025, and on 19 September an import alert let its staff hold shipments from any maker not on the list without testing them. Of 48 GLP-1 ingredient sites the agency inspected or assessed through records requests, 21% were out of compliance with manufacturing rules or did not answer in time, and the FDA described sites that registered, refused its records requests and then deregistered within a short period.

    accessdata.fda.govfrierlevitt.com

    Credit

    FDA

  6. 2026

    A quarter on copies

    Researchers at the University of Michigan and the VA Ann Arbor Healthcare System asked 322 US adults who reported at least three months on weekly semaglutide or tirzepatide injections, recruited online, to photograph their medicine. Two coders, working separately, classed 26% of the photos as compounded products, and 65% of those users had said they were taking one of the four branded drugs.

    LessonWhat users say they take is not a reliable record of whether it is a copy.

    europepmc.org

    Credit

    J. M. Katz, A. N. Gearhardt and D. H. Griauzde

  7. 2026

    Generics where patents ended

    Novo Nordisk's patent on semaglutide expired in India on 21 March 2026, and Sun Pharma, Dr Reddy's, Zydus and Glenmark launched generic versions, one of them for long-term weight management. The brand had cost about ₹8,800 to ₹11,000 a month there; Dr Reddy's priced its pen at about ₹4,200 a month. On 28 April 2026 Health Canada approved Dr Reddy's semaglutide, the first generic in a G7 country, for type 2 diabetes only.

    thesouthfirst.comglobalnews.ca

    Credit

    Sun Pharma, Dr Reddy's, Zydus and Glenmark; Health Canada

Watch for

  1. Limits on copy ingredients

    On 6 February 2026 FDA Commissioner Martin Makary said the agency intends to take "decisive steps" to restrict GLP-1 drug ingredients meant for unapproved compounded drugs that companies, Hims & Hers among them, mass-market as alternatives to approved drugs, and warned of seizure and court injunctions. Warning letters to 30 telehealth companies were announced on 3 March. On 1 May 2026 the FDA proposed to leave semaglutide, tirzepatide and liraglutide off its list of bulk ingredients that outsourcing facilities, the larger compounders it inspects, may use, and it later extended comments to 30 July 2026; a search of the Federal Register on 20 November 2026 found no final decision.

    Achieved whena final rule, import action or court order restricts these ingredients, and an outside count shows fewer compounded GLP-1 offers.

    fda.govfederalregister.govfederalregister.gov

    Claimed by

    FDA, February and May 2026

  2. Impurities found by a maker

    Scientists at Novo Nordisk report that follow-on and compounded samples of semaglutide and liraglutide carried impurities that differ from Novo's own products, including chains with amino acids missing or added, that some impurity fragments were presented to immune cells in laboratory tests in ways that could provoke an immune response, and that compounded semaglutide lost strength and gained impurities when exposed to light.

    Achieved whena laboratory with no tie to a maker of these drugs reproduces the differences on samples bought on the open market and publishes its methods.

    europepmc.org

    Claimed by

    K. L. Kopp and colleagues, Novo Nordisk, July 2026

Open

  1. 01

    Every lab test, one table

    One public table of every published laboratory test of semaglutide or tirzepatide sold outside the approved supply: compounded by pharmacies, sold online without a prescription, labeled "for research" or counterfeit. Each row is one tested product, with where and when it was bought, the type and country of the seller, the lab, whether the lab is accredited, who paid for the test, and each result: content against the label, purity, endotoxin, sterility and the impurities named.

    The brief
    Credit · unclaimed
  2. 02

    Count the research-peptide shops

    A monthly, repeatable count of websites that sell GLP-1 drugs labeled "for research purposes" or "not for human consumption", found by fixed search queries: how many there are, which drugs they list (including retatrutide, which no regulator has approved), whether their pages give dosing instructions or ship to consumers, and which payment methods they accept. Only the counts are published; the list of sites goes to regulators and payment networks, so that the work does not become a shopping guide.

    The brief
    Credit · unclaimed

Open 01 · the brief

Every lab test, one table

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

One public table of every published laboratory test of semaglutide or tirzepatide sold outside the approved supply: compounded by pharmacies, sold online without a prescription, labeled "for research" or counterfeit. Each row is one tested product, with where and when it was bought, the type and country of the seller, the lab, whether the lab is accredited, who paid for the test, and each result: content against the label, purity, endotoxin, sterility and the impurities named.

Why it is still open

The results sit in separate papers and filings, each testing a few products and paid for by different parties. Ashraf and colleagues tested three vials from illegal online sellers, and Novo Nordisk's own scientists tested follow-on and compounded samples. The FDA publishes counts of adverse event reports, 990 for compounded semaglutide and more than 730 for compounded tirzepatide by 31 May 2026, but no table of test results. A search of Europe PMC in November 2026 found no review that gathers the tests.

europepmc.orgeuropepmc.orgfda.gov

Built with what exists

the Europe PMC and Crossref APIs to find papers; FDA warning letters and import alerts; court filings on CourtListener, where lawsuits between drug makers and compounders can include test results; an AI model such as Claude to draft rows from each source, with a person checking every number; a spreadsheet and a GitHub repository.

  1. First step

    Enter every product tested by Ashraf and colleagues (2024) and Kopp and colleagues (2026) into the table's columns.

  2. Done looks like

    At least 30 tested products from at least 10 sources, every value linked to its source, the funder recorded for every row, and a summary of the share of products outside their labeled strength by type of seller, published under an open license.

Open 02 · the brief

Count the research-peptide shops

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A monthly, repeatable count of websites that sell GLP-1 drugs labeled "for research purposes" or "not for human consumption", found by fixed search queries: how many there are, which drugs they list (including retatrutide, which no regulator has approved), whether their pages give dosing instructions or ship to consumers, and which payment methods they accept. Only the counts are published; the list of sites goes to regulators and payment networks, so that the work does not become a shopping guide.

Why it is still open

The FDA says it has warned companies selling semaglutide, tirzepatide, retatrutide, survodutide and mazdutide falsely labeled for research, products "sold directly to consumers for human use with dosing instructions." Ashraf and colleagues surveyed illegal online pharmacies once, with web data from 2023, and N. K. R. Sehgal and colleagues at the University of Pennsylvania studied what retatrutide users report on social media; a search of Europe PMC in November 2026 found no repeated count of the sellers.

fda.goveuropepmc.orgeuropepmc.org

Built with what exists

a search API and a crawler such as Scrapy or Playwright run on a fixed schedule; an AI model such as Claude or Gemini to label each page against a written codebook, with a person checking a random sample; the FDA's public warning-letter pages to match sellers; the team's own archive of page snapshots.

  1. First step

    Write the search queries and the coding sheet, run them once, and code the first 50 storefronts by hand.

  2. Done looks like

    Twelve monthly snapshots, at least 100 storefronts tracked, the AI labels agreeing with a person on at least 90% of a checked sample of 200 pages, and a published table of counts by drug and month.